Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-01-11 @ 3:34 PM
Study NCT ID:
NCT03808805
Status:
COMPLETED
Last Update Posted:
2025-12-03
First Post:
2018-09-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009196', 'term': 'Myeloproliferative Disorders'}], 'ancestors': [{'id': 'D001855', 'term': 'Bone Marrow Diseases'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077608', 'term': 'Aprepitant'}, {'id': 'D006919', 'term': 'Hydroxyzine'}], 'ancestors': [{'id': 'D009025', 'term': 'Morpholines'}, {'id': 'D010078', 'term': 'Oxazines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010879', 'term': 'Piperazines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Phase 3, randomized prospective study, double blind-double placebo'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 63}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-04-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-08', 'completionDateStruct': {'date': '2024-08-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-26', 'studyFirstSubmitDate': '2018-09-26', 'studyFirstSubmitQcDate': '2019-01-15', 'lastUpdatePostDateStruct': {'date': '2025-12-03', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2019-01-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )', 'timeFrame': 'at 15 days', 'description': 'number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)'}], 'secondaryOutcomes': [{'measure': 'Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )', 'timeFrame': 'at 60 days', 'description': 'number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)'}, {'measure': 'Cessation of pruritus', 'timeFrame': 'at 15 days', 'description': 'number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) )'}, {'measure': 'Cessation of pruritus', 'timeFrame': 'at 60 days', 'description': 'number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms))'}, {'measure': 'Time observed to decreased the VAS to 3/10', 'timeFrame': '01 to 60 days', 'description': 'number of days to obtain an intensity of pruritus at 3/10 on the VAS (Visual Analogue Scale )'}, {'measure': 'Duration of treatment effectiveness', 'timeFrame': '1 to 60 days', 'description': 'number of days the VAS (Visual Analogue Scale ) is below (or equal) 3/10'}, {'measure': 'Adverse event occurring during the association therapeutic', 'timeFrame': 'at 15 days', 'description': 'type of adverse event occuring during the treatment period'}, {'measure': 'Number of prematurely discontinued anti-pruritic treatment', 'timeFrame': 'at 15 days', 'description': 'Total number of prematurely discontinued treatments for all subjects'}, {'measure': 'Complete blood count (normal or abnormal)', 'timeFrame': '1 to 60 days', 'description': 'number of patients with hematologic remission : hematocrit \\<45% with leukocytes \\<10 giga/l and platelets \\<400 giga/l'}, {'measure': 'Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire', 'timeFrame': 'at J0 (day of inclusion)', 'description': 'Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire', 'timeFrame': 'at J0 (day of inclusion)', 'description': 'Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire', 'timeFrame': 'at 15 days', 'description': 'Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers)questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire', 'timeFrame': 'at 15 days', 'description': 'Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaires : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire', 'timeFrame': 'at 30 days', 'description': 'Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire', 'timeFrame': 'at 30 days', 'description': 'Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire', 'timeFrame': 'at 45 days', 'description': 'Evaluation of quality of life by completion of the MPN-SAF(Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire', 'timeFrame': 'at 45 days', 'description': 'Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire', 'timeFrame': 'at 60 days', 'description': 'Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire'}, {'measure': 'Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire', 'timeFrame': 'at 60 days', 'description': 'Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire'}, {'measure': 'Quantification of the change of plasma concentrations of cytokines and neuropeptides', 'timeFrame': 'at J0 (day of inclusion)', 'description': 'Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)'}, {'measure': 'Quantification of the change of plasma concentrations of cytokines and neuropeptides', 'timeFrame': 'at 15 days', 'description': 'Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)'}, {'measure': 'Quantification of the change of plasma concentrations of cytokines and neuropeptides', 'timeFrame': 'at 30 days', 'description': 'Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)'}, {'measure': 'Quantification of the change of plasma concentrations of cytokines and neuropeptides', 'timeFrame': 'at 60 days', 'description': 'Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Myeloproliferative Disorder', 'Aquagenic Pruritus']}, 'referencesModule': {'references': [{'pmid': '34923994', 'type': 'DERIVED', 'citation': 'Le Gall-Ianotto C, Verdet R, Nowak E, Le Roux L, Gasse A, Fiedler A, Carlhant-Kowalski D, Marcorelles P, Misery L, Ianotto JC. Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP. Trials. 2021 Dec 19;22(1):938. doi: 10.1186/s13063-021-05864-8.'}]}, 'descriptionModule': {'briefSummary': 'Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.', 'detailedDescription': 'Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value \\>5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis)\n* and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months\n* and suffering of persistent aquagenic pruritus\n* and with a pruritus intensity on Analogic Visual Scale \\>5/10\n* patients who gave their written consent for participation in the study\n\nExclusion Criteria:\n\n* patients with a physical or psychological disability to sign the consent form\n* patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin\n* patients already included in another therapeutic protocol\n* patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo\n* patients already on anti-anxiety and / or anti-depressant treatment\n* patients with absolute contraindications to the use of Aprepitant or Hydroxyzine\n* hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients\n* lactose intolerance\n* pregnant or lactating women'}, 'identificationModule': {'nctId': 'NCT03808805', 'acronym': 'APHYPAP', 'briefTitle': 'Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms', 'organization': {'class': 'OTHER', 'fullName': 'University Hospital, Brest'}, 'officialTitle': 'Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.', 'orgStudyIdInfo': {'id': 'ApHyPAP 29BRC18.0036'}, 'secondaryIdInfos': [{'id': '2018-000426-66', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'studied group', 'description': 'Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days', 'interventionNames': ['Drug: Aprepitant 80 mg', 'Drug: Placebo of Hydroxyzine']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'comparative group', 'description': 'Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days', 'interventionNames': ['Drug: Hydroxyzine 25mg', 'Drug: Placebo of Aprepitant']}], 'interventions': [{'name': 'Aprepitant 80 mg', 'type': 'DRUG', 'description': 'oral therapy - daily dose - 14 days', 'armGroupLabels': ['studied group']}, {'name': 'Hydroxyzine 25mg', 'type': 'DRUG', 'description': 'oral therapy - daily dose - 14 days', 'armGroupLabels': ['comparative group']}, {'name': 'Placebo of Hydroxyzine', 'type': 'DRUG', 'description': 'oral therapy - daily dose - 14 days', 'armGroupLabels': ['studied group']}, {'name': 'Placebo of Aprepitant', 'type': 'DRUG', 'description': 'oral therapy - daily dose - 14 days', 'armGroupLabels': ['comparative group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '29609', 'city': 'Brest', 'state': 'Brest Cedex', 'country': 'France', 'facility': 'CHRU de Brest - Hôpital Morvan', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'zip': '29107', 'city': 'Quimper', 'state': 'Quimper', 'country': 'France', 'facility': 'Centre Hospitalier de Cornouaille', 'geoPoint': {'lat': 47.99597, 'lon': -4.09795}}, {'zip': '49933', 'city': 'Angers', 'country': 'France', 'facility': "CHU d'Angers", 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'zip': '14033', 'city': 'Caen', 'country': 'France', 'facility': 'CHU de Caen', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '29171', 'city': 'Douarnenez', 'country': 'France', 'facility': 'Centre Hospitalier de Douarnenez', 'geoPoint': {'lat': 48.09542, 'lon': -4.32904}}, {'zip': '38043', 'city': 'Grenoble', 'country': 'France', 'facility': 'CHU Grenoble Alpes', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'zip': '69373', 'city': 'Lyon', 'country': 'France', 'facility': 'Centre Léon Bérard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '29672', 'city': 'Morlaix', 'country': 'France', 'facility': 'Centre Hospitalier des Pays de Morlaix', 'geoPoint': {'lat': 48.57784, 'lon': -3.82792}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'CHU de Nantes', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'city': 'Rennes', 'country': 'France', 'facility': 'Hôpital Pontchaillou', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '22027', 'city': 'Saint-Brieuc', 'country': 'France', 'facility': 'Hôpital Yves Le Foll', 'geoPoint': {'lat': 48.51513, 'lon': -2.76838}}], 'overallOfficials': [{'name': 'Jean-Christophe IANOTTO, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hématologie Clinique-Institut de Cancéro-Hématologie'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital, Brest', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}